Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to combat obesity. Is TERN stock a good buy right now?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
NASH treatments are projected to be one of the most sought-after indications in the coming years.
NASH is a surprisingly common ailment, and the first treatments are on the way.
The company is showing progress toward a NASH therapy.
March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices closed lower for a fourth straight session, with Nasdaq dropping the most as market participants'...
FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant...
FOSTER CITY, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
- Dr. Russell to report to Dr. Erin Quirk, President and Head of Research & Development FOSTER CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Terns...